Close

Archive for category: News

Effects of a systemic enzyme therapy in healthy active adults after exhaustive eccentric exercise: a randomized, two-stage, double-blinded, placebo-controlled trial.

Marzin T, Lorkowski G, Reule C, et al. 2017.

 

Wobenzym® plus supplementation before and after exercise increased maximum concentric strength in medium performance athletes and improved inflammatory, metabolic and immune biomarkers in all subjects.

Clinical trial shows Wobenzym® has a significant effect on exercise-induced fatigue, muscle soreness and damage in endurance athletes

Study confirms substantial and significant effects of Wobenzym® in attenuating exercise-induced muscle damage and delayed onset muscle soreness in endurance athletes

Pittsburgh, PA, March 13, 2017 – A new study published today in BMJ Open Sport & Exercise Medicine shows promising results for Wobenzym®, a form of systemic enzyme therapy (SET), in mediating muscle fatigue, reducing soreness, and attenuating potential muscle damage in endurance athletes. Researchers at The Sports School at Fuerstenfeldbruck-Puch Germany conducted the trial, using Wobenzym plus contributed by Mucos Pharma, a subsidiary of Atrium Innovations.

Exercise-induced muscle damage (EIMD) and its most common symptom, delayed onset muscle soreness (DOMS), can impact an athlete’s training frequency and performance. This trial investigated the effects of SET before and after exhaustive eccentric exercise on functional and biochemical parameters of EIMD and DOMS in male sportsmen with medium performance level.

Researchers at The Sports School at Fuerstenfeldbruck-Puch Germany administered Wobenzym in a randomized, placebo-controlled trial to male athletes aged 20-50 in order to examine the effects of SET on fatigue, muscle soreness and damage, as well as on immunological and metabolic biomarkers. Using Wobenzym before and after exhaustive eccentric exercise helped maintain strength and reduce pain in less resistance-trained, endurance athletes while showing significant favorable effects in inflammatory, metabolic and immune biomarkers in all subjects.

These positive results may be due in part to Wobenzym’s role in mediating the body’s natural inflammatory processes. Wobenzym may affect EIMD and DOMS by balancing the inflammatory response to stress and damage incurred by exercise.

“This study confirms there is a substantial and significant effect of SET on fatigue, muscle soreness and damage, as well as immunological and metabolic markers,” explained Tobias Marzin, lead researcher. “The use of Wobenzym in this trial showed a significant reduction in inflammatory biomarkers training across all levels, indicating that SET supports normal inflammatory processes for muscle recovery and may be an alternative for clinicians in the treatment of muscle fatigue and soreness.”

Mucos Pharma GmbH & Co. KG contributed Wobenzym® for use in this study.

For more information, view the full study.

About Mucos Pharma
MUCOS Pharma, headquartered in Berlin, has an extensive history in Systemic Enzyme Therapy spanning over 50 years. Mucos offers the Wobenzym® product range throughout Europe, Asia and the Americas and is globally recognized in the joint health market. Wobenzym products, in addition to their rich clinical history, are well-known within the medical community for numerous benefits in the health of joints, muscles, and tendons. MUCOS Pharma prides itself on bringing high quality systemic enzyme products to patients and practitioners worldwide.

About Atrium Innovations
Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based, natural health products that are distributed in more than 35 countries. The company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education. Atrium has over 1,300 employees and operates seven manufacturing facilities, all of which comply with Current Good Manufacturing Practices. The family of Atrium Innovations brands includes Pure Encapsulations, Garden of Life, Wobenzym®, Genestra Brands, Douglas Laboratories and Klean Athlete.

Update on our Growing Together Program

Our collective purpose across Atrium Innovations is to EMPOWER HEALTHIER LIVES. We cherish this mandate and work towards its fulfillment each and every day by delivering scientifically sound, innovative and quality natural health supplements, that enable people to live longer, healthier lives. We also believe in the importance of giving back to those in need. Back in 2010, Atrium Innovations created the Growing Together Program. The mission of this initiative is to make a positive and lasting impact on the health of those in need, in both the developing world and within the communities in which we live and work. Promoting health and well-being is a fundamental value that defines not only what we do, but who we are.

 We are particularly proud that the Growing Together Program has been spearheaded and driven by Atrium’s employees from around the world. Each of our business units is represented on the program’s steering committee, and people from virtually every level of our organization have been involved in the effort in one capacity or another. As part of our Growing Together Program, our partnership with SOS Children’s Villages has resulted in many wonderful and impactful endeavors that have helped support vulnerable children in Peru, Haiti, the United States, Germany and Canada. Since 2010, Atrium has raised over $520,000CDN for SOS initiatives. Below are a few of the highlights:

Going forward, we intend to continue to partner with this wonderful organization, to provide further assistance to children and families in need. Of course our Growing Together Program goes far beyond our partnership with SOS children’s Villages and sees us engaging in a variety of important community activities and making considerable contributions to various local organizations in the communities in which we live and work. Some of our participation in 2016 has included a donation to the Fort McMurray fire relief initiative and contributions to local foods banks. Garden of Life also raised over $20,000 for Special Olympics Palm Beach thanks to their annual GoL Sun Run, while Atrium continued its ongoing sponsorship of local up and coming athletes, as well as initiated a myriad of diverse fundraising initiatives throughout the year to support the community and those in need.

Indeed much to be proud of, yet so much more still to do.

Atrium Innovations appoints Jason Zhang as Managing Director of Asia Pacific & Greater China

Atrium Innovations is recognized worldwide as an innovative leader in the development, manufacturing, and commercialization of science-based nutritional health products of the highest quality. We have leading brands such as Garden of Life, the #1 brand in the natural products industry in the U.S., and Pure Encapsulations a leader in the professional channel in the U.S. and key markets throughout Europe. Currently, Atrium Innovations participates in about half of the total global market for supplements.

A key priority for Atrium Innovations is to enter new markets with its leadership brands. Asia Pacific, the largest supplement market in the world and specifically China, the 2nd largest market globally, has been the focus of our recent efforts. China represents a significant opportunity as many Chinese consumers desire foreign brands, especially “clean” brands with natural ingredients. Atrium just recently launched its Garden of Life brand into China this fall via cross border e-Commerce. Offering a full line of certified USDA Organic and Non GMO Project Verified supplements, Garden of Life is a perfect fit to meet the needs of the Chinese consumer.

To help us spearhead our recent launch into China, I am pleased to announce the appointment of Mr. Jason Zhang as Managing Director of Asia Pacific & Greater China, effective November 16, 2016. Jason will be responsible for helping establish Atrium Innovations as a leading supplement business in Asia Pacific, with his initial focus being on building our presence in China. Once this launch has been successfully established, Jason will be responsible for helping Atrium further expand its brands into other key markets within the Asia Pacific region.

Jason brings over 20 years of diverse business leadership experience, with a finely tuned expertise in China. Most recently, Jason occupied the position of Country Manager for Blackmores in China. Earlier in his career, Jason served as Director of Consulting for Kantar Retail, where he helped leading companies such as Colgate, Pepsi, Unilever and Mars develop market entry plans into the Asia Pacific marketplace.

Jason has a Law degree from Suzhou University in China and an MBA from Leeds University in the UK.

We are extremely pleased to have Jason join us and look forward to much success with this new expansion into the Asia Pacific market.

Peter Luther
President & CEO

Atrium Innovations Receives Nutrition Business Journal Award for Achievement in Science and Innovation

Barry_Ritz_award

Barry Ritz, Vice President of Scientific and Regulatory Affairs for Atrium Innovations Accepts 2016 NBJ Business Award for Achievement in Science and Innovation.

Leading industry publication praises company’s dedication to furthering the science behind supplements.

Montreal (Quebec), June 21, 2016 — Atrium Innovations Inc., a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based, nutritional supplements, has been named the recipient of the prestigious 2016 NBJ Business Award for Achievement in Science and Innovation. The Nutrition Business Journal formally presented the award last week as part of the 2016 NBJ Summit in Dana Point, California, praising the company’s history of leading innovation and long-standing commitment to being on the forefront of furthering the science and education behind nutritional supplements.

“At Atrium Innovations, we are committed to investing in research, and leveraging that research to develop safe, effective products for healthcare practitioners and health-conscious consumers. We are devoted to doing things the right way — that begins with our research efforts, and carries through to our ingredient sourcing, strict manufacturing requirements and quality assurance process,” said Barry Ritz, Vice President of Scientific and Regulatory Affairs for Atrium Innovations. “It is truly an honor to be recognized for this commitment to science and industry thought leadership.”

Atrium Innovations’ unique applied clinical research program not only focuses on the research and innovation of Atrium’s own products, but also serves to elevate the status of nutrition science through cutting-edge research and innovative partnerships. Recently, Atrium brand Pure Encapsulations launched a $1 million, multi-year partnership with the Cleveland Clinic Center for Functional Medicine supporting initiatives in clinical research, education, medical curriculum development, and policy change. Atrium has also engaged in a multi-year, multi-million dollar partnership with the Institute of Nutrition and Functional Foods at Laval University that focuses on investigating the role of nutrition on cardiometabolic health. This partnership has not only yielded key findings in the field of nutrition science but has also led to the development of several new formulas backed by clinical findings. In addition to these efforts, Atrium actively supports top academic partners worldwide on an ongoing basis through the provision of study products, matched placebos and technical expertise. Atrium’s continuous advancement of nutrition science, both through applied clinical research and investigator-initiated programs, has resulted in the publication of over 26 original research papers in peer-reviewed scientific journals to date, with another 20 studies still in progress.

For more information about the NBJ award, read the 2016 awards issue.

For more information about Atrium Innovations’ commitment to research, please visit atrium-innovations.com/research.

About Atrium Innovations
Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing and commercialization of innovative, science-based, natural health products that are distributed in more than 35 countries. The company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education. Atrium has over 1,300 employees and operates seven manufacturing facilities, all of which comply with Current Good Manufacturing Practices. The family of Atrium Innovations brands includes Pure Encapsulations, Garden of Life, Wobenzym, Genestra Brands, Douglas Laboratories and Klean Athlete.

Additional information is available at atrium-innovations.com.

INAF/Laval University PhD Candidate wins Award for Best Oral Presentation at Experimental Biology Conference

Janie

Janie Allaire, at the Experimental Biology Conference in San Diego.

Janie Allaire, a PhD candidate at the Institute of Nutrition and Functional Foods at Laval University, was awarded Best Oral Presentation at the Experimental Biology Conference in San Diego this month. This prestigious distinction, selected from nearly 1,000 other applicants, was granted for Janie’s presentation titled “DHA is more potent than EPA in attenuating cardiometabolic risk in men and women: a randomized double-blind, placebo-controlled crossover trial.”

This compelling research aims to address the data gap regarding the differential effects of EPA vs. DHA in cardiometabolic health. In this soon-to-be published trial, results showed an enhanced role of DHA in addressing inflammatory markers and plasma lipid levels than EPA. Dr. Benoît Lamarche, Janie’s advisor and Chair of Nutrition at INAF, says “We are very proud of this large clinical trial, one of the largest and most comprehensive to date. This project and Janie’s work will definitely lead to a better understanding of this apparent difference between EPA and DHA in mediating cardiometabolic effects.”

Atrium Innovations congratulates Janie on this honor and is proud to have contributed to this important research through provision of the study material used in this project. This contribution is part of a larger commitment by Atrium to investigate the impact of nutrition on cardiometabolic health at Laval University. The Canadian Institute for Health Research provided the funding for this study.

About Experimental Biology

This multidisciplinary, scientific meeting features plenary and award lectures, pre-meeting workshops, oral and posters sessions, on-site career services and exhibits of an array of equipment, supplies and publications required for research labs and experimental study. Experimental Biology is an annual meeting comprised of over 14,000 scientists and exhibitors representing six sponsoring societies and multiple guest societies.

General fields of study include anatomy, biochemistry and molecular biology, investigative pathology, nutrition, pharmacology, and physiology. Experimental Biology 2016 is open to all members of the sponsoring and guest societies and nonmembers with interest in research and life sciences. The majority of scientists represent university and academic institutions as well as government agencies, non-profit organizations and private corporations.

About Atrium Innovations

Our research program aims to not only advance the science behind our current products and promote product innovation, but also to elevate the status of nutrition science in general. In the past 5 years, we have dedicated millions of dollars to key research initiatives in nutrition and health and supported top academic partners worldwide. Click here for more about our Research Program.

2016 Nutrition Business Journal (NBJ) Award for Achievement in Science and Innovation

Atrium Innovations is the recipient of the 2016 Nutrition Business Journal (NBJ) Award for Achievement in Science and Innovation. This award is an outstanding recognition of our track record of leading innovation and our long standing commitment to being on the forefront of furthering the science behind supplements. Our longstanding commitment to scientific research differentiates us and our brands, and is the reason healthcare professionals and other advisors recommend and trust our brands above others.

The Nutrition Business Journal highlights Atrium Innovation’s many strategic partnerships and collaborations with leading research centers and top academic partners worldwide, as well as outlines our firm commitment to innovation and advancing the state of nutrition science. Check the link for the full article.

Research and Polyphenols

Atrium Innovations engaged in the development of two research videos highlighting our work with the Institute of Nutrition and Functional Foods at Laval University in Quebec. 

The first video is an overview of our partnership with universities and, most specifically, INAF and our umbrella program studying cardiometabolic health. 

The second video is a thorough exploration of Atrium Innovation’s most recent studies investigating the health benefits of polyphenols.

Prebiotic shows promise in regulating kids’ appetites

Summary: The obesity epidemic among children has caused alarm throughout the United States and Canada. Achieving healthy energy intake among this age group is a widespread health concern. The potential role of prebiotic fiber for appetite regulation in children was recently investigated.

Source: Federation of American Societies for Experimental Biology (FASEB)